The use of tyrosine kinase inhibitors in modifying the response of tumor microvasculature to radiotherapy

Bo Lu, Eric T. Shinohara, Eric Edwards, Ling Geng, Jiahuai Tan, Dennis E. Hallahan

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

The response of the tumor microvasculature to ionizing radiation can be modified to improve tumor control in preclinical mouse models of cancer. Recent studies have shown that a variety of cancer drugs can improve the response of cancers to radiotherapy. Protein tyrosine kinase inhibitors (TKIs) have been shown to enhance radiation-induced destruction of tumor blood vessels. Among these compounds are inhibitors of a broad spectrum of receptor tyrosine kinases (RTKs). Inhibition of RTKs attenuates downstream signaling from various angiogenic growth factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). RTK inhibitors with various specificities against the receptors for VEGF, PDGF, and FGF manifest significant antiangiogenic activities as well. We have shown using tumor vascular window model and tumor growth delay assays that these compounds can enhance tumor radiation response by attacking tumor microvasculature. Furthermore, we have shown that radiation and RTK inhibitors exert their antiangiogenic effect through inhibition of the PI3K/Akt signaling pathway, which results in induction of apoptosis. Our studies have provided a basis for future clinical investigations of combining radiotherapy and RTK inhibitors.

Original languageEnglish
Pages (from-to)691-698
Number of pages8
JournalTechnology in Cancer Research and Treatment
Volume4
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Dive into the research topics of 'The use of tyrosine kinase inhibitors in modifying the response of tumor microvasculature to radiotherapy'. Together they form a unique fingerprint.

Cite this